FTSE MIB
33.340,89 +154,00 (+0,46%) Dow Jones
39.164,06 +36,26 (+0,09%) Nasdaq
17.858,68 +53,53 (+0,30%) Nikkei 225
39.583,08 +241,54 (+0,61%) Petrolio
82,38 +0,64 (+0,78%) Bitcoin EUR
57.396,59 +382,10 (+0,67%)
TELA Jul 2024 7.500 put
| Chiusura precedente | 2,9600 |
| Aperto | 1,6000 |
| Denaro | 2,3000 |
| Domanda | 4,9000 |
| Prezzo d'esercizio | 7,50 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 1,6000 - 2,9600 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 11 |
GlobeNewswireTELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase. TELA’s management is scheduled to present at the Gilmartin Group Emerging Growth Compan
- GlobeNewswire
TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
New addition expands reconstruction options for surgeons and patientsMALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced the launch of their OviTex PRS Long-Term Resorbable product. OviTex PRS Long-Term Resorbable is intended for i
- GlobeNewswire
TELA Bio Reports Second Quarter 2023 Financial Results
MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Revenue of $14.5 million in the second quarter, representing growth of 39% over the second quarter of
